Lophius starts multiple sclerosis project at the BioPark
The company founded from the University of Regensburg specialises in the development and production of novel testing methods focusing on infectious diseases and autoimmune disease. The company uses so-called T-cells, a group of white blood cells that is necessary for immunity. In the framework of a biopharm competition promoted by the Federal Ministry for Research, in the consortium of winners: “NEU2 = German word for NEW novel substances for the treatment of neurological disease, the company was contracted with the development of a novel T-cell based testing process with which multiple sclerosis can be diagnosed and course of the disease followed. Uptake into the consortium offers the company the opportunity to work together with leading MS experts and speed up the development of the T-Track MS-Test-Kit. Lophius uses its own so-called Reverse T Cell Technology (RTT) to detect disease specific activated T-cells. Proof of an initial concept has already been successful in cooperation with the Clinic and Polyclinic for Neurology at the University of Regensburg and the Institute for Neuroimmunology and Clinical MS-Research at the Centre for Molecular Neurobiology in Hamburg.
For more information see: